Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (December 2023)
14 slides from Bio-gene Technology's investor presentation, Dec 12, 2023
Slide 1: Perspectives on Control of Vector-borne Diseases
Perspectives on Control of Vector-borne Diseases Bio-Gene Technology Ltd 12 December 2023 Catherine A. Hill, Ph.D. Professor & Head Department of Entomology Purdue University [email protected] Photo credit: James Gathany, CDC Opinions are those of the author and not Purdue University
Slide 2: Vector-borne Diseases & Public Health
Vector-borne Diseases & Public Health • Diseases transmitted by mosquitoes, ticks, flies • Malaria, arboviruses, Lyme borreliosis, rickettsiosis, anaplasmosis/ehrlichiosis, Chagas • Approximately half world population at risk • Morbidity and mortality • 1/6th of illness and disability A global brief
Slide 3: Increasing Risks of Vector-borne Diseases
Increasing Risks of Vector-borne Diseases • Global rise of infectious diseases • 40 new human pathogens recognized since 1970 (WHO) • Increasing risk of zoonotic pathogen spillover to humans • Over population, competition for natural resources, global travel, population dense cities, habitat loss, c
Slide 4: Need for New Vector Control Technologies
Need for New Vector Control Technologies • Lack of effective vaccines and therapeutics • Insecticides are the backbone of control (~75% via insecticides) • Dwindling arsenal of pest control tools • Pesticide resistance widespread • No new products developed for Sparks and Lorsbach. Pest. Manag. Sci.
Slide 5: Life in a warmer, more populated world?
Life in a warmer, more populated world? • Increase/decrease of VBDs • Geographic range shifts of vectors • Expanded seasonal activity of vectors • Increase in vector competence • Epidemics more common • “Epidemic belts” will expand
Slide 6: Increasing Malaria Risk in the U.S.
Increasing Malaria Risk in the U.S. • Summer 2023, first case reports of local malaria transmission (Florida, Texas) in 20 years • Malaria declared eradicated in U.S. in 1950s • Malaria vectors present in U.S. • Much of U.S. considered at increasing risk for malaria transmission
Slide 7: Malaria: Re-emerging Global Threat
Malaria: Re-emerging Global Threat • Increase in global incidence of malaria for first time since 2015 (WHO) • Anopheles stephensi, Asian malaria vector • Invasive species threat in Africa • Increased risk of urban/rural malaria transmission (50M people at risk) • Potential for continuous transmissi
Slide 8: Chagas Disease in the U.S.
Chagas Disease in the U.S. • ~300K human cases Chagas/year in the U.S. • Less than 1% cases diagnosed and treated • Associated with serious, long-term health issues (morbidity) • Vectors and reservoirs in most U.S. states U.S. Centers for Disease Control and Prevention
Slide 9: Need for New Insecticide Classes
Need for New Insecticide Classes • 36 classes insecticides recognized • Based on Modes of Action (IRAC) • Mosquito control relies on 5 classes (organochlorines, carbamates, SPs, OPs, neonicotinoids) • Will remain primary method of control • Recognized vector control product development path
Slide 10: Interest in Natural Products & Derivatives
• ~ 60% insecticides derive Interest in from NPs Natural • Excellent source of new modes of action Products & • Attractive safety profiles, Derivatives regulatory path
Slide 11: Evaluation of Bio-Gene Technology at Purdue
Evaluation of Bio-Gene Technology at Purdue Mosquito Efficacy Studies • Public health & consumer markets • FlavocideTM & QCideTM • Potent, rapid activity against larvae, adults • Contact & spatial efficacy • Synergistic activity (potentiate existing product classes) • Novel mode of action (new insec
Slide 12: Evaluating Bio-Gene Materials for Tick Control
Evaluating Bio-Gene Materials for Tick Control • Tick & TBD threats increasing globally • ~3-fold increase in TBD cases, 7 new TBDs identified (2004-2016) (CDC Vital Signs, 2018) • ~300K cases Lyme disease/year in U.S. • New products needed for public health, consumer markets Photo credit: MCEVBD
Slide 13: Evaluating Bio-Gene Materials for Tick Control
Evaluating Bio-Gene Materials for Tick Control • $10M CDC Regional Center of Excellence • Evaluate FlavocideTM & QCideTM for tick control • Contact efficacy against ticks in lab (meet EPA targets) • Residual activity in lab • Small cage and semi-field trials Spring-Summer 2024
Slide 14: Thank you
Thank you
Bio-Gene Technology — Investor Presentation (December 2023) on 6ix